<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02726295</url>
  </required_header>
  <id_info>
    <org_study_id>2015-11-044-002</org_study_id>
    <nct_id>NCT02726295</nct_id>
  </id_info>
  <brief_title>The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keimyung University Dongsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keimyung University Dongsan Medical Center</source>
  <brief_summary>
    <textblock>
      Chronic constipation is a prevalent, burdensome gastrointestinal disorder whose treatment
      remains challenging. There exist effective pharmacological therapies for chronic
      constipation, however, many patients do not well respond to current medications. Evidence
      suggests that disturbance in the gastrointestinal microbiota may be implicated in chronic
      constipation. Although, E.coli Nissle 1917 (Mutaflor®) has been used for chronic
      constipation, there are limited data regarding the efficacy of E.coli Nissle 1917 (Mutaflor®)
      in these patients. Therefore, this study aimed to investigate the efficacy of E.coli Nissle
      1917 (Mutaflor®) in patients with chronic constipation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relief of constipation defined by improvement of complete spontaneous bowel movements(CSBMs/week)</measure>
    <time_frame>28days</time_frame>
    <description>Subjects will report symptoms by questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of average number of CSBMs/week</measure>
    <time_frame>28days</time_frame>
    <description>Subjects will report symptoms by questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to 1st CSBM or SBM</measure>
    <time_frame>28days</time_frame>
    <description>Subjects will report symptoms by questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of constipation related quality of life</measure>
    <time_frame>28days</time_frame>
    <description>Subjects will report symptoms by questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of constipation related symptom</measure>
    <time_frame>28days</time_frame>
    <description>Subjects will report symptoms by questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>E. coli Nissle 1917 (Mutaflor®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mutaflor® group will receive E. coli Nissle 1917 (Mutaflor®) 28mg 2T tid for initial 2 days, then E. coli Nissle 1917, Mutaflor® 4T qd for the next 26 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo group will receive placebo drug 28mg 2T tid for initial 2 days, then placebo 4T qd for the next 26 days. Placebo drug has same shape and size with E. coli Nissle 1917 (Mutaflor®).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E. coli Nissle 1917(Mutaflor®)</intervention_name>
    <arm_group_label>E. coli Nissle 1917 (Mutaflor®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Matched placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male or female outpatients aged from 20 to 75 years old.

          -  Patients meet International Congress of Gastroenterology (ROME III) clinical criteria
             for constipation*:

        A. Must include two or more of the following:

          1. Straining in &gt; 1/4 defecations;

          2. Lumpy or hard stools &gt; 1/4 defecations;

          3. Sensation of incomplete evacuation in 1/4 defecations;

          4. Sensation of anorectal obstruction/blockage in &gt; 1/4 defecations;

          5. &lt;3 defecations/week.

        B.Loose stools are rarely present without the use of laxatives. C.There are insufficient
        criteria for irritable bowel syndrome. *Criteria fulfilled for the last 3 months with
        symptom onset at least 6 months prior to diagnosis.

        Exclusion Criteria:

          -  Pregnant or lactating woman

          -  Known organic gastrointestinal disease

          -  Subjects who diagnosed advanced adenoma within 3 years

          -  Prior gastrointestinal surgery (except appendectomy, herniotomy)

          -  Subjects who diagnosed irritable bowel syndrome

          -  Use of one or more of listed medications within 2 weeks (Laxative, Metoclopramide,
             Domperidone, Itopride, Levosulpride, Cisapride, Mosapride, Tegaserod, Prucalopride,
             Renzapride, Erythromycin, buspirone, Sumatriptan, Alosetron, Cilansetron, ondansetron,
             Citalopram, Paroxetine, Baclofen, Sildenafil, Nitroglycerin)

          -  Subjects who diagnosed lactulose malabsorption

          -  Subjects who diagnosed liver cirrhosis, severe congestive heart failure, severe renal
             insufficiency, uncontrolled hypertension, endocrine disorder, metabolic disorder,
             prior malignancy, immune deficiency

          -  Suspected obstruction, gastric retention, ileus, perforation, fecal impaction or
             inflammatory bowel disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoo Jin Lee, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>56 Dalseong-Ro, Jung-Gu, Daegu, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jung Eun Shin, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Dankook Univ. Hospotal (31116) 201 Manghyang-ro, Dongnam-gu, Cheonan, Chung Nam, South Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yoo Jin Lee</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2016</study_first_submitted>
  <study_first_submitted_qc>March 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2016</study_first_posted>
  <last_update_submitted>October 2, 2017</last_update_submitted>
  <last_update_submitted_qc>October 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Keimyung University Dongsan Medical Center</investigator_affiliation>
    <investigator_full_name>YooJin Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

